Connect with us

International

The 2020 Outcomes Creativity Index (OCI)

The 2020 Outcomes Creativity Index (OCI)

Published

on

2020 represents the second edition of the Outcomes Creativity Index (OCI), a ranking of pharmaceutical companies and prescription brands according to creativity and innovation. The OCI is an aggregate score-based creative achievement encompassing results from these leading U.S. and international healthcare award shows: The Outcomes LLC/Med Ad News Manny Awards; Cannes Lions; LIA: Health & Wellness; Clio Health; The One Show; The MM&M Awards; The Global Awards; and The Creative Floor Awards. Every year in the October issue of Med Ad News, the top 10 pharma companies and top 10 prescription brands are presented from tabulating the results of the OCI scoring system.

The OCI is based on aggregate points for the measurement period by brand and by company based on results from the aforementioned eight healthcare communications award shows. The time frame for the 2020 OCI rankings ranges from the August 2019 Creative Floor Awards show through the June 2020 Manny Awards ceremony (Cannes Lions results were not available for tabulation in the 2020 OCI rankings because of the global COVID-19 pandemic).

The World’s Smallest Booth (Lartruvo), Eli Lilly

The leading scorer in the 2020 OCI is Eli Lilly, which was the marketer for the OCI’s top-scoring prescription brand Lartruvo before the medicine was withdrawn from the marketplace. Lilly’s award-recognized campaigns include “Get Up Alarm Clock” (Lartruvo), “Puzzlehead” (Migraine disease awareness), “Journal of Me” (Plaque psoriasis), “Chaos Within” (Cyramza), “Emgality Tackles Migraine Market at the Speed of Social,”  “Last Voicemail” (Jardiance), and “Don’t Miss a Beat” (Sharecare).

Johnson & Johnson/Janssen scored the second-highest point total among marketers in the 2020 OCI, led by a variety of campaigns for Tremfya and psoriasis awareness. Lilly’s award-recognized campaigns include “Commitment to Harmony,” “Life Sucked Out,”  “Nurses Save Lives,” 5B, Antion “Life Inside You,” schizophrenia awareness, Remicade, Xarelto, “The Untold Episodes” (Janssen Pharmaceuticals), “Voices of Relapse” (Janssen Neuroscience), “Michael’s World” (Care4Today), and “Out of the Dark, Special Powers” (Janssen).

Commitment to Harmony (Tremfya/Psoriasis), Janssen/J&J

The third-leading point scorer in the 2020 OCI is GlaxoSmithKline. GSK’s award-recognized campaigns include “Breath of Life,” Shingrix Personal Intelligence Marketing Relationship Marketing Campaign for HCPs, Pronamel Intensive Repair Launch, The Multiple Paths Campaign (Ellipta portfolio), Theraflu Flu Tracker, Abreva Director’s Mix Campaign, Bexsero – 24 Hours (MenB), Sensodyne.com, “Optimized for Success,” Buckley’s Syrup 100 Years of Awful Taste Campaign, Tums (TummerTime), “We See Your Pain,” United by BCMA, ovarian cancer awareness (Tesaro), “Not on My Watch” (Tesaro), U=U= HIV Awareness Campaign, “As Much As I Can – Using Experiential Theater to Reduce HIV Stigma,” and the Triumeq Moving Forward Website.

Med Ad News talked to GlaxoSmithKline’s Dipal Patel, VP, Vaccines Commercialization Leader, Shingrix (formerly VP, Commercial Head, Respiratory, Emerging Markets), about the company’s “Breath of Life” campaign, which was one of the highest-scoring campaigns during the OCI 2020 time frame.

Med Ad News: What were the challenges you faced, and how did creativity help you overcome those challenges? 

Dipal Patel: In China, whilst incidence of COPD is high and growing, awareness is low amongst patients. In addition treatment is often taken for short periods to time, which is not how a chronic disease such as COPD should be treated. The genesis of breath of life was to tap into the local customs and raise awareness of COPD and impact on breathing in a manner that the Chinese patient could relate with. A COPD patient has more difficulty breathing out than breathing in. Blow painting is popular amongst older Chinese people and requires the painter to blow breath to move the paint on the paper. This is why we used the blow painting creative to symbolize the importance of breath and more importantly the art of breathing out.

Med Ad News: What does creativity and innovation mean to you in pharmaceutical marketing, and why is it important? 

Dipal Patel: Creativity is very important in pharmaceutical marketing. Though the creativity has to mean something to the consumer/individual/physician. It has to speak to the user, trigger an association with an experience or memory, and elicit an emotional response. The beauty of breath of life was that it was based on local insights, spoke to the local consumer and customers. Often in my Industry our creative is too rational with little or no emotional connection.

Med Ad News:: What does it mean to you to be recognized as the most innovative and creative marketers in the industry?

Breath of Life (COPD), GlaxoSmithKline

Dipal Patel: This is a huge achievement for GSK. Our ambition is to deliver impactful campaigns that help the consumer understand their condition/disease better. It also demonstrated the magic a great company/agency partnership can deliver. The breath of life took courage on part of both GSK and McCann to create something which was innovative, edgy, and used interactive technology to connect with the consumer.

Med Ad News: What were the objectives and messages of the brand creativity and innovation? 

Dipal Patel: Our intent was to take an art that was familiar to the target age group and use it to raise awareness of COPD/make COPD interesting by allowing the consumer to interact with the art using their own breath. The trees that are drawn by blowing into the mini program are distinct and eye catching for each user.  The mini program was developed to enable the consumer to understand their lung health and seek further consultation with their healthcare professional.

 

TOP 10 COMPANIES

Company: Total Points

1.Eli Lilly: 79

2. Johnson & Johnson: 67

3. GlaxoSmithKline: 65 

4. Sanofi: 38 

5. Novartis: 31

6. Regeneron: 27 

7. Amgen: 25

8. AbbVie: 23 

8. Pfizer: 23 

10. Merck: 21

 

TOP 10 PRESCRFIPTION BRANDS

Prescription Brand (Company)

1. Lartruvo (Eli Lilly) 

2. Tremfya (Johnson & Johnson)

A Beautiful Pair (Eylea), Regeneron

3. Eylea (Regeneron Pharmaceuticals) 

4. Nuplazid (Acadia Pharmaceuticals)

5. Trulance (Salix Pharmaceuticals)

6. Alprolix (Sanofi/Bioverativ) 

7. Lonhala Magnair (Sunovion Pharmaceuticals) 

8. Dupixent (Sanofi and Regeneron) 

9. Jardiance (Boehringer Ingelheim and Eli Lilly)

10. Arikayce (Insmed) 

 

ABOUT THE AWARD SHOWS

Manny Awards

For more than 30 years, the Manny Awards have paid tribute to the creative work of agencies serving the healthcare market, their people, and their contributions to the industry. Each year at this black-tie gala, Med Ad News and agency professionals come together to acknowledge those making significant contributions to, and celebrate creative excellence in, healthcare communications. On this special evening, hundreds of peers join Med Ad News to honor winners in an extensive range of award categories. The accolades include three Agency of the Year categories, Industry Person of the Year, Agency on the Rise, Most Creative Agency, and the Heart Award for philanthropic/social causes. Due to the global COVID-19 pandemic, the 2020 event was held virtually on June 18 and can be viewed for free On Demand at https://portal.xyvid.com/mannyawards2020 

LIA Awards: Pharma and Health & Wellness 

Found in 1986, the London International Awards (LIA) stands as a champion of the creative process, creatives themselves, and of course fantastic creative work. Created for creatives, LIA is a show striving for honesty and openness. LIA is rapidly rising to become one of the industry’s most important shows. In large part this is due to Creative LIAisons, a weeklong event held each year in Las Vegas concurrently with judging. The 2019 winners were revealed during early November. Due to the global COVID-19 pandemic, the 2020 awards and their associated Creative LIAisons program were canceled but will resume during 2021 once the COVID-19 crisis has passed.

Clio Health 

Built on Clio’s enduring reputation for recognizing the most creative and culturally relevant marketing and communications, Clio Health was founded in 2009 to celebrate the work behind wellness. The program is a barometer for excellence in a highly specialized field, recognizing creativity that not only meets the advanced needs of consumers, but addresses the sophisticated challenges, demands and opportunities of a fast-evolving, rapidly expanding global marketplace and industry. The 2019 winners were announced on Dec. 9. Due to the global COVID-19 pandemic, the 2020/2021 winners will be revealed by April 2021.

One Show 

The One Show is one of the world’s most prestigious awards shows in advertising, design and digital marketing that celebrates excellence in creativity of ideas and quality of execution. Established in 1973 and produced by non-profit organization The One Club for Creativity, The One Show is recognized for the high level of integrity in the event’s judging procedures and processes. Due to the global COVID-19 pandemic, the 2020 winners were presented online over two days during June 17-18.

MM&M Awards 

The MM&M Awards celebrate excellence in all facets of healthcare marketing and communications within the life sciences industry. With more than 80 judges, the MM&M Awards are the result of deep analysis and expertise amongst esteemed panels of leaders and thinkers representing a wide variety of disciplines and backgrounds within healthcare marketing communities. The 16th annual MM&M Awards show was held in New York City on Oct. 10, 2019. The 2020 winners were announced virtually on Oct. 8.

Global Awards 

The Global Awards – celebrating 25 years with the November 2019 event – are dedicated to excellence in healthcare & wellness and pharma advertising and communications on an international basis. Honoring the World’s Best Health & Wellness and Pharma Advertising from all over the world, the competition extends over regional, national and continental boundaries to provide a comprehensive 360° worldview of advertising and corporate communications in the international health & wellness and pharma community. The Global Awards receives entries from healthcare corporations, hospitals, advertising agencies, pharmaceutical companies, production companies, design studios, etc. that produce communications for healthcare & wellness, pharmaceutical, and medical entities and causes. Due to the global COVID-19 pandemic, the event was not held during 2020 but will return in 2021.

Creative Floor Healthcare Awards 

With August 2019 marking the London event’s sixth year, The Creative Floor – billed as “The Toughest Healthcare Award Show on Earth” – continues to be the only health and wellness award show in the world to donate a percentage of profits to help more diversity and help underprivileged talent break into the healthcare communications industry. Winners of the awards decide how the money is spent. Due to the global COVID-19 pandemic, the event was not held during 2020 but will return in 2021.

Cannes Lions: Pharma and Health & Wellness

Cannes Lions is a five-day International Festival of Creativity and the largest gathering in the creative marketing community. The Health Track consists of the Pharma Lions and Health & Wellness Lions. Lions Health is a two-day forum that focuses on the creation, conception and execution of awe-inspiring life-changing creativity that has a verifiable impact on healthcare outcomes. The Health & Wellness and Pharma Lions celebrate creativity in branded communications in this highly innovative but fiercely regulated sector with the unique power to truly change lives. Due to the global COVID-19 pandemic, the 67th Cannes Lions International Festival of Creativity scheduled for June 22-26, 2020, was postponed but the event will return in 2021.

 

Read More

Continue Reading

International

Red Candle In The Wind

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by…

Published

on

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by printing at 275,000 against a consensus call of 200,000. We say superficially, because the downward revisions to prior months totalled 167,000 for December and January, taking the total change in employed persons well below the implied forecast, and helping the unemployment rate to pop two-ticks to 3.9%. The U6 underemployment rate also rose from 7.2% to 7.3%, while average hourly earnings growth fell to 0.2% m-o-m and average weekly hours worked languished at 34.3, equalling pre-pandemic lows.

Undeterred by the devil in the detail, the algos sprang into action once exchanges opened. Market darling NVIDIA hit a new intraday high of $974 before (presumably) the humans took over and sold the stock down more than 10% to close at $875.28. If our suspicions are correct that it was the AIs buying before the humans started selling (no doubt triggering trailing stops on the way down), the irony is not lost on us.

The 1-day chart for NVIDIA now makes for interesting viewing, because the red candle posted on Friday presents quite a strong bearish engulfing signal. Volume traded on the day was almost double the 15-day simple moving average, and similar price action is observable on the 1-day charts for both Intel and AMD. Regular readers will be aware that we have expressed incredulity in the past about the durability the AI thematic melt-up, so it will be interesting to see whether Friday’s sell off is just a profit-taking blip, or a genuine trend reversal.

AI equities aside, this week ought to be important for markets because the BTFP program expires today. That means that the Fed will no longer be loaning cash to the banking system in exchange for collateral pledged at-par. The KBW Regional Banking index has so far taken this in its stride and is trading 30% above the lows established during the mini banking crisis of this time last year, but the Fed’s liquidity facility was effectively an exercise in can-kicking that makes regional banks a sector of the market worth paying attention to in the weeks ahead. Even here in Sydney, regulators are warning of external risks posed to the banking sector from scheduled refinancing of commercial real estate loans following sharp falls in valuations.

Markets are sending signals in other sectors, too. Gold closed at a new record-high of $2178/oz on Friday after trading above $2200/oz briefly. Gold has been going ballistic since the Friday before last, posting gains even on days where 2-year Treasury yields have risen. Gold bugs are buying as real yields fall from the October highs and inflation breakevens creep higher. This is particularly interesting as gold ETFs have been recording net outflows; suggesting that price gains aren’t being driven by a retail pile-in. Are gold buyers now betting on a stagflationary outcome where the Fed cuts without inflation being anchored at the 2% target? The price action around the US CPI release tomorrow ought to be illuminating.

Leaving the day-to-day movements to one side, we are also seeing further signs of structural change at the macro level. The UK budget last week included a provision for the creation of a British ISA. That is, an Individual Savings Account that provides tax breaks to savers who invest their money in the stock of British companies. This follows moves last year to encourage pension funds to head up the risk curve by allocating 5% of their capital to unlisted investments.

As a Hail Mary option for a government cruising toward an electoral drubbing it’s a curious choice, but it’s worth highlighting as cash-strapped governments increasingly see private savings pools as a funding solution for their spending priorities.

Of course, the UK is not alone in making creeping moves towards financial repression. In contrast to announcements today of increased trade liberalisation, Australian Treasurer Jim Chalmers has in the recent past flagged his interest in tapping private pension savings to fund state spending priorities, including defence, public housing and renewable energy projects. Both the UK and Australia appear intent on finding ways to open up the lungs of their economies, but government wants more say in directing private capital flows for state goals.

So, how far is the blurring of the lines between free markets and state planning likely to go? Given the immense and varied budgetary (and security) pressures that governments are facing, could we see a re-up of WWII-era Victory bonds, where private investors are encouraged to do their patriotic duty by directly financing government at negative real rates?

That would really light a fire under the gold market.

Tyler Durden Mon, 03/11/2024 - 19:00

Read More

Continue Reading

Government

Trump “Clearly Hasn’t Learned From His COVID-Era Mistakes”, RFK Jr. Says

Trump "Clearly Hasn’t Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President…

Published

on

Trump "Clearly Hasn't Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President Joe Biden claimed that COVID vaccines are now helping cancer patients during his State of the Union address on March 7, but it was a response on Truth Social from former President Donald Trump that drew the ire of independent presidential candidate Robert F. Kennedy Jr.

Robert F. Kennedy Jr. holds a voter rally in Grand Rapids, Mich., on Feb. 10, 2024. (Mitch Ranger for The Epoch Times)

During the address, President Biden said: “The pandemic no longer controls our lives. The vaccines that saved us from COVID are now being used to help beat cancer, turning setback into comeback. That’s what America does.”

President Trump wrote: “The Pandemic no longer controls our lives. The VACCINES that saved us from COVID are now being used to help beat cancer—turning setback into comeback. YOU’RE WELCOME JOE. NINE-MONTH APPROVAL TIME VS. 12 YEARS THAT IT WOULD HAVE TAKEN YOU.”

An outspoken critic of President Trump’s COVID response, and the Operation Warp Speed program that escalated the availability of COVID vaccines, Mr. Kennedy said on X, formerly known as Twitter, that “Donald Trump clearly hasn’t learned from his COVID-era mistakes.”

“He fails to recognize how ineffective his warp speed vaccine is as the ninth shot is being recommended to seniors. Even more troubling is the documented harm being caused by the shot to so many innocent children and adults who are suffering myocarditis, pericarditis, and brain inflammation,” Mr. Kennedy remarked.

“This has been confirmed by a CDC-funded study of 99 million people. Instead of bragging about its speedy approval, we should be honestly and transparently debating the abundant evidence that this vaccine may have caused more harm than good.

“I look forward to debating both Trump and Biden on Sept. 16 in San Marcos, Texas.”

Mr. Kennedy announced in April 2023 that he would challenge President Biden for the 2024 Democratic Party presidential nomination before declaring his run as an independent last October, claiming that the Democrat National Committee was “rigging the primary.”

Since the early stages of his campaign, Mr. Kennedy has generated more support than pundits expected from conservatives, moderates, and independents resulting in speculation that he could take votes away from President Trump.

Many Republicans continue to seek a reckoning over the government-imposed pandemic lockdowns and vaccine mandates.

President Trump’s defense of Operation Warp Speed, the program he rolled out in May 2020 to spur the development and distribution of COVID-19 vaccines amid the pandemic, remains a sticking point for some of his supporters.

Vice President Mike Pence (L) and President Donald Trump deliver an update on Operation Warp Speed in the Rose Garden of the White House in Washington on Nov. 13, 2020. (Mandel Ngan/AFP via Getty Images)

Operation Warp Speed featured a partnership between the government, the military, and the private sector, with the government paying for millions of vaccine doses to be produced.

President Trump released a statement in March 2021 saying: “I hope everyone remembers when they’re getting the COVID-19 Vaccine, that if I wasn’t President, you wouldn’t be getting that beautiful ‘shot’ for 5 years, at best, and probably wouldn’t be getting it at all. I hope everyone remembers!”

President Trump said about the COVID-19 vaccine in an interview on Fox News in March 2021: “It works incredibly well. Ninety-five percent, maybe even more than that. I would recommend it, and I would recommend it to a lot of people that don’t want to get it and a lot of those people voted for me, frankly.

“But again, we have our freedoms and we have to live by that and I agree with that also. But it’s a great vaccine, it’s a safe vaccine, and it’s something that works.”

On many occasions, President Trump has said that he is not in favor of vaccine mandates.

An environmental attorney, Mr. Kennedy founded Children’s Health Defense, a nonprofit that aims to end childhood health epidemics by promoting vaccine safeguards, among other initiatives.

Last year, Mr. Kennedy told podcaster Joe Rogan that ivermectin was suppressed by the FDA so that the COVID-19 vaccines could be granted emergency use authorization.

He has criticized Big Pharma, vaccine safety, and government mandates for years.

Since launching his presidential campaign, Mr. Kennedy has made his stances on the COVID-19 vaccines, and vaccines in general, a frequent talking point.

“I would argue that the science is very clear right now that they [vaccines] caused a lot more problems than they averted,” Mr. Kennedy said on Piers Morgan Uncensored last April.

“And if you look at the countries that did not vaccinate, they had the lowest death rates, they had the lowest COVID and infection rates.”

Additional data show a “direct correlation” between excess deaths and high vaccination rates in developed countries, he said.

President Trump and Mr. Kennedy have similar views on topics like protecting the U.S.-Mexico border and ending the Russia-Ukraine war.

COVID-19 is the topic where Mr. Kennedy and President Trump seem to differ the most.

Former President Donald Trump intended to “drain the swamp” when he took office in 2017, but he was “intimidated by bureaucrats” at federal agencies and did not accomplish that objective, Mr. Kennedy said on Feb. 5.

Speaking at a voter rally in Tucson, where he collected signatures to get on the Arizona ballot, the independent presidential candidate said President Trump was “earnest” when he vowed to “drain the swamp,” but it was “business as usual” during his term.

John Bolton, who President Trump appointed as a national security adviser, is “the template for a swamp creature,” Mr. Kennedy said.

Scott Gottlieb, who President Trump named to run the FDA, “was Pfizer’s business partner” and eventually returned to Pfizer, Mr. Kennedy said.

Mr. Kennedy said that President Trump had more lobbyists running federal agencies than any president in U.S. history.

“You can’t reform them when you’ve got the swamp creatures running them, and I’m not going to do that. I’m going to do something different,” Mr. Kennedy said.

During the COVID-19 pandemic, President Trump “did not ask the questions that he should have,” he believes.

President Trump “knew that lockdowns were wrong” and then “agreed to lockdowns,” Mr. Kennedy said.

He also “knew that hydroxychloroquine worked, he said it,” Mr. Kennedy explained, adding that he was eventually “rolled over” by Dr. Anthony Fauci and his advisers.

President Donald Trump greets the crowd before he leaves at the Operation Warp Speed Vaccine Summit in Washington on Dec. 8, 2020. (Tasos Katopodis/Getty Images)

MaryJo Perry, a longtime advocate for vaccine choice and a Trump supporter, thinks votes will be at a premium come Election Day, particularly because the independent and third-party field is becoming more competitive.

Ms. Perry, president of Mississippi Parents for Vaccine Rights, believes advocates for medical freedom could determine who is ultimately president.

She believes that Mr. Kennedy is “pulling votes from Trump” because of the former president’s stance on the vaccines.

“People care about medical freedom. It’s an important issue here in Mississippi, and across the country,” Ms. Perry told The Epoch Times.

“Trump should admit he was wrong about Operation Warp Speed and that COVID vaccines have been dangerous. That would make a difference among people he has offended.”

President Trump won’t lose enough votes to Mr. Kennedy about Operation Warp Speed and COVID vaccines to have a significant impact on the election, Ohio Republican strategist Wes Farno told The Epoch Times.

President Trump won in Ohio by eight percentage points in both 2016 and 2020. The Ohio Republican Party endorsed President Trump for the nomination in 2024.

“The positives of a Trump presidency far outweigh the negatives,” Mr. Farno said. “People are more concerned about their wallet and the economy.

“They are asking themselves if they were better off during President Trump’s term compared to since President Biden took office. The answer to that question is obvious because many Americans are struggling to afford groceries, gas, mortgages, and rent payments.

“America needs President Trump.”

Multiple national polls back Mr. Farno’s view.

As of March 6, the RealClearPolitics average of polls indicates that President Trump has 41.8 percent support in a five-way race that includes President Biden (38.4 percent), Mr. Kennedy (12.7 percent), independent Cornel West (2.6 percent), and Green Party nominee Jill Stein (1.7 percent).

A Pew Research Center study conducted among 10,133 U.S. adults from Feb. 7 to Feb. 11 showed that Democrats and Democrat-leaning independents (42 percent) are more likely than Republicans and GOP-leaning independents (15 percent) to say they have received an updated COVID vaccine.

The poll also reported that just 28 percent of adults say they have received the updated COVID inoculation.

The peer-reviewed multinational study of more than 99 million vaccinated people that Mr. Kennedy referenced in his X post on March 7 was published in the Vaccine journal on Feb. 12.

It aimed to evaluate the risk of 13 adverse events of special interest (AESI) following COVID-19 vaccination. The AESIs spanned three categories—neurological, hematologic (blood), and cardiovascular.

The study reviewed data collected from more than 99 million vaccinated people from eight nations—Argentina, Australia, Canada, Denmark, Finland, France, New Zealand, and Scotland—looking at risks up to 42 days after getting the shots.

Three vaccines—Pfizer and Moderna’s mRNA vaccines as well as AstraZeneca’s viral vector jab—were examined in the study.

Researchers found higher-than-expected cases that they deemed met the threshold to be potential safety signals for multiple AESIs, including for Guillain-Barre syndrome (GBS), cerebral venous sinus thrombosis (CVST), myocarditis, and pericarditis.

A safety signal refers to information that could suggest a potential risk or harm that may be associated with a medical product.

The study identified higher incidences of neurological, cardiovascular, and blood disorder complications than what the researchers expected.

President Trump’s role in Operation Warp Speed, and his continued praise of the COVID vaccine, remains a concern for some voters, including those who still support him.

Krista Cobb is a 40-year-old mother in western Ohio. She voted for President Trump in 2020 and said she would cast her vote for him this November, but she was stunned when she saw his response to President Biden about the COVID-19 vaccine during the State of the Union address.

I love President Trump and support his policies, but at this point, he has to know they [advisers and health officials] lied about the shot,” Ms. Cobb told The Epoch Times.

“If he continues to promote it, especially after all of the hearings they’ve had about it in Congress, the side effects, and cover-ups on Capitol Hill, at what point does he become the same as the people who have lied?” Ms. Cobb added.

“I think he should distance himself from talk about Operation Warp Speed and even admit that he was wrong—that the vaccines have not had the impact he was told they would have. If he did that, people would respect him even more.”

Tyler Durden Mon, 03/11/2024 - 17:00

Read More

Continue Reading

International

There will soon be one million seats on this popular Amtrak route

“More people are taking the train than ever before,” says Amtrak’s Executive Vice President.

Published

on

While the size of the United States makes it hard for it to compete with the inter-city train access available in places like Japan and many European countries, Amtrak trains are a very popular transportation option in certain pockets of the country — so much so that the country’s national railway company is expanding its Northeast Corridor by more than one million seats.

Related: This is what it's like to take a 19-hour train from New York to Chicago

Running from Boston all the way south to Washington, D.C., the route is one of the most popular as it passes through the most densely populated part of the country and serves as a commuter train for those who need to go between East Coast cities such as New York and Philadelphia for business.

Veronika Bondarenko captured this photo of New York’s Moynihan Train Hall. 

Veronika Bondarenko

Amtrak launches new routes, promises travelers ‘additional travel options’

Earlier this month, Amtrak announced that it was adding four additional Northeastern routes to its schedule — two more routes between New York’s Penn Station and Union Station in Washington, D.C. on the weekend, a new early-morning weekday route between New York and Philadelphia’s William H. Gray III 30th Street Station and a weekend route between Philadelphia and Boston’s South Station.

More Travel:

According to Amtrak, these additions will increase Northeast Corridor’s service by 20% on the weekdays and 10% on the weekends for a total of one million additional seats when counted by how many will ride the corridor over the year.

“More people are taking the train than ever before and we’re proud to offer our customers additional travel options when they ride with us on the Northeast Regional,” Amtrak Executive Vice President and Chief Commercial Officer Eliot Hamlisch said in a statement on the new routes. “The Northeast Regional gets you where you want to go comfortably, conveniently and sustainably as you breeze past traffic on I-95 for a more enjoyable travel experience.”

Here are some of the other Amtrak changes you can expect to see

Amtrak also said that, in the 2023 financial year, the Northeast Corridor had nearly 9.2 million riders — 8% more than it had pre-pandemic and a 29% increase from 2022. The higher demand, particularly during both off-peak hours and the time when many business travelers use to get to work, is pushing Amtrak to invest into this corridor in particular.

To reach more customers, Amtrak has also made several changes to both its routes and pricing system. In the fall of 2023, it introduced a type of new “Night Owl Fare” — if traveling during very late or very early hours, one can go between cities like New York and Philadelphia or Philadelphia and Washington. D.C. for $5 to $15.

As travel on the same routes during peak hours can reach as much as $300, this was a deliberate move to reach those who have the flexibility of time and might have otherwise preferred more affordable methods of transportation such as the bus. After seeing strong uptake, Amtrak added this type of fare to more Boston routes.

The largest distances, such as the ones between Boston and New York or New York and Washington, are available at the lowest rate for $20.

Read More

Continue Reading

Trending